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               Dedicated to my grandfather...  
                                                                       Gone though you have, I heard your voice today, 
                                                              I tried to make out what the words might mean,  
                                                                 Like something seen half-clearly on a screen,         
                                                                Gone since you have, grief too in time will go,  
                                                                      Or share space with old joy; it must be so, 
Rest then in peace, but spare some elation,  
Death cannot put down every conversation,  
Over and out, as you once used to say, 
Not on your life. You're in these lines to stay. 
                                                                              (With permission from, The Guardian*) 
 
ABSTRACT 
The Ras subfamily of Rho GTPases plays an important role in myriads of cell 
processes, such as actin cytoskeleton dynamics, membrane trafficking and cell 
migration. Additionally, they also participate in diverse signal transduction pathways 
that regulate gene transcription, cell survival and cell growth. The ability of these 
proteins to function as a signaling molecule depends on their capacity to cycle between 
an active GTP-bound conformation and an inactive GDP-bound conformation. Till 
date, three Rho family members namely, RhoA, Rac1 and Cdc42 have been well 
studied as compared to other Rho family members. 
This thesis highlights a less studied Rho GTPase, RhoD, which together with Rif 
constitutes a separate subgroup of the Rho GTPases. Ectopic expression of RhoD and 
Rif has a dramatic effect on the organization of the actin filament system observed as 
long flexible filopodia protrusions and the formation of short bundles of actin 
filaments. Moreover, RhoD has a role in regulating endosome dynamics and is a 
negative regulator of cell motility. This motivated us to find out more about the 
signaling pathways downstream of RhoD. We initiated our studies by identifying a 
number of novel binding partners for RhoD for instance, FILIP1, WHAMM, 
Rabankyrin-5 and the ZIP kinase. We observed that RhoD together with FILIP1 and 
WHAMM had a distinct role in actin dynamics, cell adhesion and cell migration as 
compared to the better studied members of the Rho subfamily. Furthermore, with the 
same RhoD binding partners, we elucidated another regulatory role of RhoD in Golgi 
homeostasis and ER-to-Golgi transport measured by VSV-G protein transport assay. 
Previous studied have identified Rabankyrin-5 as a Rab5 effector. Interestingly, these 
studies also reported that Rabankyrin-5 localizes to early endosomes and to 
macropinosomes of epithelial cells. We found that Rabankyrin-5 participates in 
coordinating Rab5 and RhoD in endosome trafficking. We describe a novel 
mechanism by which RhoD, Rab5 and Rabankyrin-5 coordinate membrane 
trafficking events and endocytosis, for instance during the internalization of activated 
tyrosine kinase receptor, such as the PDGFRβ. Finally, we found that RhoD 
modulates focal adhesion dynamics and actin filament assembly through a novel 
effector, ZIP kinase. In summary, this thesis sheds light on the less studied Rho 
GTPase RhoD and provides novel insight into the mechanisms underlying its diverse 
cellular effects.  
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1. INTRODUCTION   
1.1 Synopsis 
Just as a skeleton maintains shape and posture of a human body, likewise, all eukaryotic 
cells also possess a scaffold or cytoskeleton. This is a complex yet vital network of 
filamentous proteins that transverse through the crowded cytoplasmic environment, 
giving cells shape and framework in order to accomplish vital cellular processes via the 
signals emanating from outside the cell to the cell interior.  
     The Rho subfamily of GTPases is a family of signaling proteins that belongs to the Ras 
superfamily of small GTPases. They cycle between an active GTP-bound state and an 
inactive GDP-bound state. This cycling is tightly controlled by sets of proteins namely, 
guanine nucleotide exchange factors (GEFs) that catalyze nucleotide exchange by virtue of 
GDP dissociation and GTP association, resulting in the activation of a Rho GTPase. On the 
other hand, GTPase activating proteins (GAPs) play a role by enhancing the intrinsic 
GTPase activity that results in the hydrolysis of GTP and thereby inactivating a GTPase 
(Figure 2) [1,2,3]. This way, the small GTPases can function as molecular switches.  
    The Rho GTPases regulate diverse cellular processes in their active conformation and 
they carry out their functions mainly by binding to the effector proteins. They are called 
“effectors”, because they bind to the GTP-bound form of the GTPases and are able to 
transduce signals from the activated Rho GTPases to downstream cellular responses. Till 
date, many effectors for Rho GTPases have been identified. These include protein kinases 
(i.e., tyrosine kinases, serine/threonine kinases), scaffold proteins and actin regulating 
proteins (e.g. WASP, formins, etc). It appears that the major role of Rho GTPases is to 
recruit effector proteins to a particular target site intracellularly where they can execute 
their functions (Figure 2) [4].  
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Figure 1. Rho GTPases regulate basic cellular processes [adapted from source 5]. 
 
The focus of this thesis is on a less studied member of Rho subfamily of GTPases 
known as RhoD. Together with the related GTPase Rif, it constitutes a unique subgroup 
of the classical Rho GTPases. My studies show that RhoD has profound effects via the 
effector proteins isolated during this thesis work, on the regulation of the actin filament 
system, ER-to-Golgi transport, receptor trafficking and cell migration.  
          
1.2   The Ras GTPases 
The “Ras” stands for Rat sarcoma, indicating how the first member of the protein 
family was identified. In 1964, Jennifer Harvey and Werner Kirsten first observed a 
preparation of murine leukaemia virus isolated from leukamic rats that induced 
sarcomas in newly born litters [6,7,8,9,10]. However, the genes involved in inducing 
sarcomas in rodent litters were shrouded in mystery until 1975, when Edward Scolnick 
at the National Cancer Institute, USA identified and described the first two ras genes, 
H-RAS and K-RAS from the seminal studies on the two murine sarcoma viruses 
identified by Harvey and Kirsten [10,11,12,13,14]. Subsequently, in 1979 the first 
human ras genes were identified and confirmed by three independent research 
laboratories: one headed by Robert Weinberg at the Massachusetts Institute of 
Technology, one by Geoffrey Cooper at the Harvard University, and one by Mariano 
Barbacid in collaboration with Stuart Aaronson lab at the National Institute of Health 
[10,15,16,17]. The third ras gene was identified in 1983 by research team headed by 
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Robin Weiss from the Institute of Cancer Research, UK and designated as N-RAS for 
its early identification in human neuroblastoma cells [18]. These three genes encoded 
similar proteins, comprising of around 189 amino acids (approximately 21KDa) of 
which the first 86 amino acids are identical in sequence including the effector binding 
site and homologous till amino acid residue 167 [19]. Point mutations in Ras genes 
render them GTPase deficient and thereby constitutively active converting them into 
an active oncogenes. The most common point mutation occurring in human cancer is a 
replacement of a glycine for a valine amino acid residue at position 12 of K-Ras. The 
mutation is frequently found in tumor biopsies in patients suffering from pancreatic 
adenocarcinomas, colon and lung cancers. It is therefore, well-established fact now 
that about 20-30 % of all human tumors have mutations in Ras oncogenes [20,21,22].  
      The human genome project has established that the Ras superfamily consists of over 
150 members. These members have evolutionary conserved orthologues present in 
Dictyostelium, Saccharomyces cerevisiae, Drosophila melanogaster as well as higher 
eukaryotes [23]. Based on protein sequence and functional similarities Ras superfamily 
has been further subdivided into six subfamilies summarized in (Table 1) [24].    
      
 
Ras subfamilies 
 
Cellular functions 
 Members 
(in humans) 
Ras (Rat Sarcoma) 
 
Regulates gene expression 36 
Rho (Ras homologous) 
 
Regulates actin organisation, cell cycle 
progression, gene expression 
20 
Rab (Ras-like protein 
in brain) 
 
Regulates intracellular vesicle trafficking, 
mitotic spindle and nuclear envelope 
assembly 
61 
Ran (Ras-like nuclear 
protein) 
 
Regulates nucleocytoplasmic transport of 
RNA and proteins 
1 
Arf (ADP-ribosylation 
factor) 
 
Regulates vesicular transport 27 
Miro (Mitochondrial 
Rho) 
Regulates mitochondrial dynamics 2 
 
      
Table1. The Ras protein superfamily. The Ras superfamily members are subdivided 
based on their protein sequences and functional similarities. It also highlights the role 
of small GTPases in diverse cellular processes. 
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1.3 Molecular regulation and localization of small GTPases  
1.3.1. The Rho GTPases 
The first gene encoding a Rho protein was isolated in 1985 by Pascal Madaule while 
working in Richard Axel’s group, from a cDNA library obtained from abdominal 
ganglia of the mollusc, Aplysia [25]. It was identified with low stringency cDNA screen 
and named Rho for Ras homolog (now called RhoA). The protein encoded turned out to 
share 35% homology with H-Ras [25]. Subsequently, the group of Snyderman identified 
Rac1 and Rac2 in 1989 [26]. The third member of Rho family CDC42 was first identified 
in yeast as S.cerevisiae cell division-cycle 42 and subsequently by Polakis in 1989 [27]. 
Human Cdc42 shows 80% amino acid identity with yeast CDC42, 50% and 70% 
respectively with mammalian RhoA and Rac1 proteins [26]. Till date, 20 members of the 
Rho subfamily have been identified in mammals including the well studied RhoA, Rac1 
and Cdc42 (Figure 3). As with Ras superfamily each Rho subfamily member shares a 
common highly conserved core G domain that is about 150 amino acids long and is 
liable for providing essential nucleotide exchange [1,25]. In contrast to the Ras 
superfamily, most members of the Rho family contain an additional α-helical structure 
comprising 12 amino acid residue and known as the insert region [1,2,3]. 
The Rho GTPases are also under the same GTP cycling regime as the Ras proteins but in 
addition to GEFs and GAPs, they are regulated by guanine nucleotide dissociation 
inhibitors (GDIs), which target the GDP-bound form of Rho GTPases thereby blocking 
the GTP/GDP exchange (Figure 2). The Rho GTPases can further be subdivided into 
classical and so-called atypical Rho GTPases (Figure 3). The latter proteins are not 
under the same regulatory scheme as the classical Rho GTPases. The atypical Rho 
GTPases harbor amino acid residues in their active sites, which render them 
constitutively GTP-bound. This suggests the presence of additional regulatory modes, 
such as post-translational modifications (i.e., phosphorylation or ubiquitylation) and/or 
regulation at the transcriptional level. 
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Figure 2. Rho GTPase regulation. Rho GTPases are regulated by GTPase cycle.  Small 
GTPases that belong to classical Rho subfamily cycle between an inactive GDP-bound 
state and an active GTP-bound form. Active GTPases interact with effector proteins to 
mediate a cell response [adapted from source 1]. 
 
 
 
Figure 3. An unrooted dendritic tree represents the human Rho GTPases. The 
atypical Rho GTPases are encircled and labelled. The 20 members in humans are further 
divided into 8 families (in box top right) [adapted from source 24]. 
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1.4 Regulation of Rho GTPases  
      1.4.1a. The RhoGEFs  
RhoGEFs have a pivotal role in activating small GTPases by nucleotide exchange. 
Around 80 RhoGEFs exist in humans [28]. They have been further subdivided into two 
families, the Dbl family and the DOCK (Dedicator of cytokinesis) family [29,30,31]. 
These proteins are controlled by signals emanating from outside as well as inside a cell. 
The best understood example of RhoGEF is Vav. At the N-terminus of Vav, we find a 
calponin homology (CH) domain and the catalytic GEF module. On the other hand at 
the C-terminal region lies the zinc finger domain, proline-rich region, and SH2 domain 
flanked by two SH3 domains. Upon the deletion of first 66 amino acids from the N-
terminus the Vav can be constitutively activated [32]. Vav is involved in downstream 
signaling of many receptors, for instance EGFR, PDGFR etc [33,34]. When the receptor 
is activated upon the stimuli, Vav is transiently phosphorylated intracellularly by Src and 
Syk members of tyrosine kinase family, resulting in stimulation of its catalytic activity 
[34,35,36,37,38,39]. 
        
Dbl RhoGEF family of proteins 
The first RhoGEF isolated in mammals was the Dbl. It was isolated in 1985 as an 
oncogene in NIH3T3 cells by focus formation assay using DNA from a human diffuse 
B-cell lymphoma [40,41]. Eventually, the amino acid sequence revealed similarity to 
S. cerevisiae cell-division-cycle 24 (CDC24) and it turned out to possess a potential to 
catalyze nucleotide exchange on Cdc42 in vitro [40]. A domain was found highly 
conserved between Dbl and CDC24. Subsequently, it was named as DH (Dbl 
homology) domain, constituting the core catalytic domain required for GEF activity 
[42]. Approximately, 70 proteins containing a DH domain have been identified in 
humans, however these proteins share little homology amongst each other with an 
exception of three conserved regions (CR1, CR2 and CR3) each about 10-30 amino 
acids long [29]. The DH proteins also possess a tandem pleckstrin homology (PH) 
domain adjacent to DH domain which is pivotal for intracellular targeting of DH-
domain, the DH-PH unit is the least structural domain necessary to GEF activity in 
vivo (Figure 4) [43]. The PH domains are well known to interact with phosphorylated 
phosphoinositides (PIP3) (Figure 4) [44]. Two possible functional roles have been 
suggested for PH domain, first, they could directly affect the catalytic activity of the 
DH domain; second, they could help target GEFs to their correct intracellular location. 
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An alternative function has also been suggested for the PH domain of Dbs, which is 
that it participates with the DH domain in Cdc42 binding primarily through interaction 
involving the switch II motif of the GTPase [45].  
In addition to DH-PH domains, most GEFs possess some additional domains that are 
functionally involved in the regulation of the protein, like SH2 and SH3 domains, 
serine/threonine, tyrosine kinase domains and PDZ domains. These domains are 
necessary to link GEFs to upstream receptors and signaling molecules, as well as 
regulating the catalytic activity of the RhoGEFs [28]. 
Analysis of the three-dimensional structure of the RhoGEFs Sos1, Trio (DH1) and 
Tiam show that they are composed of a flattened, elongated bundle of 11 α-helices 
[46,47,48]. Two of these 11 helices, CR1 and CR3, are exposed on the surface of the 
DH domain and participate in the formation of the GTPase interaction pocket. GEFs 
bind to the GDP bound form and destabilize the GDP–GTPase complex while 
stabilizing a nucleotide-free reaction intermediate [49]. Since the intracellular 
concentration of GTP exceeds the concentration of GDP with a factor of 10, therefore 
released GDP is replaced with GTP, leading to activation of the small GTPase. Many 
RhoGEF members are specific for a particular Rho GTPase. For instance, Fgd1 and 
Fgd5 are specific for Cdc42 [50]. Other RhoGEFs may trigger the activation of several 
small GTPases; for instance, Vav1 acts on Cdc42, Rac1 and RhoA, whereas Dbl acts 
on RhoA and Cdc42 [42,51]. Surprisingly, of the 20 Rho GTPases known, the 
specificity in activation elicited by most known GEFs has only been investigated for 
Rho, Rac and Cdc42 subgroups.     
 
                      
 
Figure 4. Schematic structure shows Dbl GEF family. Members of Dbl family 
contain DH catalytic domain adjacent to a phosphoinositide-binding PH domain 
[adapted from source 52]. 
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DOCK RhoGEF family of proteins 
 
                       
                    
Figure 5. Schematic structure of DOCK family GEFs. The members of DOCK 
family contain DHR-1 and DHR-2 domain, which are structurally different from the 
Dbl family but functionally similar. DOCK1/180 till DOCK5 are Rac specific GEFs 
and DOCK6 uptill DOCK 8 are GEFs for Rac and Cdc42. From DOCK9 till DOCK11 
bind nucleotide-free Cdc42 [adapted from source 52]. 
 
The DOCK gene was first cloned in 1996 as a gene product encoding a 180 KDa 
protein (hence the name, DOCK 180) interacting with proto-oncogene product c-Crk 
binding protein [30]. Together, DOCK 180 (nowadays called DOCK1) and its 
orthologue in Drosophila melanogaster and Caenorhabditis elegans form an 
evolutionarily conserved RhoGEF protein family sharing two highly conserved 
domains known as DHR-1 and DHR-2 (Figure 5) [29,31]. Thus far, 11 DOCK proteins 
have been identified in mammals and the members of this protein family have been 
subdivided into 4 subgroups designated as DOCK-A, DOCK-B, DOCK-C and DOCK-
D [31]. These proteins control many biologically important cellular processes. 
Interestingly, both in vitro and in vivo, the DHR-2 domain of these DOCK proteins has 
been shown to be sufficient and necessary to trigger guanine nucleotide exchange on 
GTPases (mainly Cdc42 and Rac1)(Figure 5).  
Located upstream of DHR-2 domain is the highly conserved DHR-1 domain present in 
virtually all DOCK180 related GEFs [29,31]. DHR-1 domain has been shown to effect 
interaction between phosphatidylinositol (3,5)-bisphosphate and PtdIns (3,4,5)P3 lipid 
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signaling in vitro as well as in vivo [53]. Intriguingly, Rac1 activation is inhibited upon 
the inactivation of DHR-2 domain of DOCK180 that in turn inhibits cell migration and 
other cellular processes for instance phagocytosis [31,54,55]. This emphasizes the 
importance of the DHR-2 domain in the function of the protein. 
 
1.4.1b. The RhoGAPs   
Till date, more than 80 RhoGAP proteins have been identified and characterized in 
humans.  Being so many compared to Rho GTPases itself indicates that these proteins 
are involved in negatively regulating or terminating the signals at the specific location 
intracellularly. There are considerable evidences to suggest that the activity of Rho 
GAP within a cell is controlled by diverse means for instance protein-protein 
interaction, lipid binding, post-translation modification such as phosphorylation 
[56,57,58,59,60]. The first RhoGAP was discovered in 1989 and known as Bcr 
(breakpoint cluster region) [61]. Biochemically, RhoGAPs interact with the GTP 
loaded conformation of the Rho GTPases, thereby stimulating their intrinsic GTPase 
activity up to a 100 fold [62]. The structural determination of the RhoGAP domain has 
made it possible to decipher exactly how RhoGAPs catalyse the GTPase-activating 
reaction [63,64]. Crystallographic studies have revealed that the amino acids close to 
the arginine form a catalytic site involved in direct hydrolyzing GTP reaction to GDP 
with release of an inorganic phosphate (Pi). Mutation in these residues have also 
shown to hampers the activity of RhoGAPs [65]. Despite a low degree of similarity in 
primary structure between the RhoGAP and the RasGAP domains, the tertiary folding, 
as well as the basic mechanism of RhoGAP domain appears quite similar to RasGAP 
[62]. The RhoGAP domains are formed of 9 alpha helices and the hallmark is a 
conserved arginine amino acid residue present in a loop region, the so-called “Arginine 
finger” [66].  
    
1.4.1c. The RhoGDIs 
The RhoGDIs target the GDP-bound form of Rho and Rab GTPases. Their function is to 
block the exchange by maintaining the GTPases in “OFF-state”. In addition, GDIs also 
prevent the GTPases from localizing to the plasma membrane. The first RhoGDI 
identified was RhoGDI-1 (also known as RhoGDIα) [66]. It was shown to be involved 
in blocking the dissociation of GDP form and eventually binding of GTP to small 
GTPase RhoB. Till date, only 3 RhoGDIs have been identified: RhoGDI-1, RhoGDI-2 
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(also known as D4/Ly-GDI,) and RhoGDI-3 (also known as RhoGDIγ). The GDI-1 
was initially purified from rabbit intestines and bovine brain cytosol [67]. Subsequently, 
the cDNAs of RhoGDI-1 was isolated from humans [68]. The RhoGDIs have a very 
disparate sequence at the N-terminus compared to the C-terminus. The RhoGDI-1 and 
2 share around 74 % homology (i.e., 178 amino acid region at the C-terminus) and 
RhoGDI-3 of around 63% in the same region with GDI-1 and 2 [69].  
Out of these three RhoGDIs, 1 and 2 are of cytoplasmic origin and directly involved in 
controlling the membrane targeting i.e., the membrane association/dissociation cycle 
and GTP/GDP cycle. The RhoGDI-3 acts in a different manner compared to GDI-1 
and 2. Its mode of action is therefore still unclear [68,69].  
Mutations in Cdc42 and Rac1 defective in RhoGDIα binding (due to substitution of 
Arginine 66 with Glutamic acid) are able to target to membranes and induce filopodia 
or lamellipodia formation [70,71]. Similarly, in null RhoGDIα mesangial cells, 
transfection of activated Cdc42 or Rac1 mutants exhibited the same spectrum of actin 
reorganization as the wild-type cells. This suggests that other proteins may assist in the 
solubilization of nascent Rho GTPases. Moreover, the actin reorganization mediated 
by Rac1 and Cdc42 do not rely on control by RhoGDI. However, these studies utilized 
ectopically expressed Rho GTPases, including use of activated mutants evading 
control by GAPs [70,71]. It appears that the C-terminal hypervariable regions of Rho 
family GTPases are sufficient to enable delivery to the various resident membrane 
compartments, rather than their binding to RhoGDIα [72]. Nonetheless, RhoGDI do 
control the partitioning between the cytosol, membrane compartments and may 
facilitate the targeting of GTPases to appropriate signaling sites. 
 
1.4.1d. Organization of Rho GTPase signaling pathways 
A cell has to respond to myriad of signals. Therefore, well-regulated signaling 
pathways make sure that cell responds precisely to signals. Proteins involved in signal 
transduction pathways possess multiple domains that give them a degree of flexibility 
in order to interact concurrently with variety of other proteins. Rho GTPases are 
capable of controlling the cell response by interacting with effector proteins [1,2,3]. 
Based on the upstream signals, the Rho GTPases selectively activate particular 
downstream effector proteins; thereby organizing downstream signals in a cascade that 
ultimately leads to a specific cellular response for instance, cell polarity, cell migration 
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etc. Experimental studies have confirmed the role of GEFs, GAPs in complex with 
these effector proteins, enabling the control of particular effector protein to form a 
complex with a specific Rho GTPase [1,2,3]. Therefore, based on the upstream signals, 
the Rho GTPases efficiently organize signaling pathways downstream. 
The original concept of the best studied Rho members RhoA, Rac1 and Cdc42 stated 
that they regulate stress fibers, lamellipodia and filopodia, respectively [73]. The 
molecular mechanism underlying these biological responses have been described in 
some details. For instance, RhoA regulates the formation of stress fibers through the 
concerted action of Rho-associated protein kinase (ROCK) and Diaphanous-related 
formins (DRFs). ROCK acts by activating myosin II by phosphorylating myosin-
regulating components and promoting actin filament formation via DRFs. Rac1 act via 
so-called nucleation-promoting factors (NPFs), in this particular case the WAVE 
complex induces the formation of a weave of actin filament in the protruding 
lamellipodium at the leading edge of migrating cells. Cdc42, trigger the formation of 
filopodia via a number of downstream effectors but DRFs seem to have a critical role 
in the process [74].   
 
1.5 Essential functions of Rho GTPases 
1.5.1a. Actin filament system regulation 
One of most abundant proteins present in eukaryotic cells is the actin. The 
polymerization of actin is regulated by variety of actin binding proteins. There are actin-
sequestering proteins, such as profilin, which act to keep actin in a monomeric 
unpolymerized state. Actin filament formation is brought about mainly by two groups of 
polymerization machineries, the NPFs (most notably, WASP, WAVE and WHAMM) 
and the DRFs (most notably mDia1 and mDia2) [75]. NPFs bind to the so-called Arp2/3 
complex and promote the formation of branched actin filaments, whereas DRFs promote 
the elongation of actin filaments. The organization of actin is further regulated by 
proteins that aid in promoting assembly of actin filaments into highly ordered bundles 
and meshwork. Another important regulatory cue acts through capping of actin 
filaments, which helps to keep the actin filaments stable. Finally, there are numerous 
proteins (such as cofilin) that aid in the depolymerization of actin filaments by a 
severing activity and by promoting actin filament disassembly [2,76].  
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1.5.1b. Actin polymerization via NPFs and the Arp2/3 complex 
Actin regulators trigger formation of new actin filaments by a process known as 
nucleation. Kinetically, nucleation is rate-limiting step in the actin polymerization due to 
actin dimer intermediates being highly unstable [77,78]. The actin related proteins were 
initially purified from Acanthamoeba casetellanii by affinity chromatography. These 
proteins had high affinity for the actin sequestering protein, Profilin and stabilized actin 
for the promotion of filament growth and elongation [79].  
The Arp2/3 complex consists of assembly of seven proteins [79,80]. Of these seven 
proteins, two subunits were actin-related proteins of ARP2 and ARP3 subfamilies 
(hence, the name Arp2/3 complex). Remaining 5 subunits were initially named by size 
but have now been named as ARPC1 (actin-related protein complex-1), ARPC2, 
ARPC3, ARPC4 and p16-ARPC5 (Figure 6). ARPC1 possesses two isoforms in humans 
namely, ARPC1A and ARPC1B. ARPC1 possesses WD repeats domain whereas 
ARPC-5 do not contain any common domains. A definitive role of Arp2/3 complex in 
lamellipodia formation was clarified by Bailly et al., in 2001 by using an antibody 
against Arp2/3, which inhibited EGF-stimulated lamellipodia formation [81]. The actin 
filaments in lamellipodia distinctly oriented their barbed ends (i.e., fast growing ends) 
towards the cell membrane (Figure 6). The Arp 2/3 complex binds to the sides and 
pointed ends of the pre-existing actin filaments in a manner that contributes to its 
activation (Figure 6) [82]. Binding to NPFs is also essential in the activation of the 
Arp2/3 complex. The Arp2/3 complex nucleates actin filament by mimicking actin 
trimer with two of its subunits binding to actin monomers. The best studied role of 
Arp2/3 was performed by Welch et al., in 1997 where they showed how bacterium 
Listeria monocytogenes left an arc trajectory in the cytoplasm of platelets cells and 
comet-like tail rich in short actin filaments with their barbed ends towards the bacterium 
[83]. The Arp2/3 was subsequently purified from these platelets cells. This meant that 
the polymerization of actin monomers at the bacterial surface was coupled with 
propulsion indicating that it provides motile forces at the leading edges [84,85,86].  
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           Figure 6. The Arp2/3 complex. The Arp2/3 complex and others actin related proteins 
(ARPC1-ARPC5) linking two filamentous actins together [adapted from source 87]. 
 
Immediately after the Arp 2/3 isolation and its characterization, it became apparent 
that this complex by itself has weak in vitro nucleating ability leading to a conviction 
that certain cellular factors must be required in order to trigger the nucleation and 
branching by the Arp2/3 complex. Eventually, many Arp2/3-binding NPFs were 
isolated. They can be divided into two subclasses: Type 1 NPFs include Wiskott-
Aldrich syndrome protein (WASp), neural WASp (N-WASp), WASp family verprolin 
homologous protein (WAVE also called SCAR), WASp and SCAR homologue 
(WASH), WASp homolog associated with actin, membrane and microtubules 
(WHAMM) and Junction-mediating and-regulatory protein (JMY). All these proteins 
possess verprolin-homology domain (VCA domain or also called WH2), the central 
(Cofilin homology domain) and the acidic domain consisting of three conserved motifs 
which allow globular actin binding [88]. The Type II nucleation-promoting factors 
most notably cortactin lack VCA domains [89]. However, this class of NPFs have 
acidic domain at their amino terminus which binds directly with Arp2/3 complex [89].  
The Cdc42 triggers the activation of Arp2/3 through WASp and N-WASp. Cdc42 
interacts with N-WASp directly in vivo freeing an intra-molecular and auto-inhibitory 
interaction thereby exposing C-terminus of Arp2/3 binding and activation site (Figure 
7) [2]. Rac1 has been shown to act mainly via the WAVE family of proteins and the 
so-called WAVE complex (Figure 7). The WAVE proteins are constitutively 
associated with four additional proteins namely: Sra1/Cyfip1, Nap1/Hem-2, Abi and 
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HSPC300 [90]. Rac1 binds Sra1 and triggers the dismantling of this inactive complex, 
thereby letting WAVE to interact directly with Arp2/3 [2,91].  
                
Figure 7. Actin polymerization mediated by the Rho GTPases. Rac1 and Cdc42 
activate Arp2/3 via WASP and WAVE in order to initiate a branched filament network 
[adapted from source 1]. 
                          
                                           
 
Figure 8. Rho GTPases and formins. Rho triggers the activation of formins that in turn 
promotes linear elongation of filaments at the barbed ends [adapted from source 1]. 
 
Actin polymerization via DRFs 
In eukaryotic cells, another mechanism for actin polymerization is through Formin 
protein family [92]. The formins are a large family of proteins that facilitate the 
nucleation of new filaments by promoting the interaction between two actin monomers. 
In addition to nucleation, formins also facilitate the elongation of actin filaments, 
exclusively at the barbed ends. The formin mDia1 (also known as Dia1, Drf1 for 
Diaphanous-related formin-1) is the mouse homologue of the diaphanous homolog 1 of 
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Drosophila. This protein was identified in a yeast two-hybrid screen as  RhoA effector 
and it triggers actin filament elongation (Figure 8). In yeast, there are only two formins 
known Bnr1 and Bni1 that stimulate the Rho mediated actin polymerization. In 
mammals, formins function downstream of Rho to form focal contacts and stress 
fibers. In Saccharomyces cerevisiae, they function downstream of Cdc42 to induce 
actin filament formation in an Arp2/3 independent manner [93,94]. Their function 
appears to include nucleation of new actin filaments [95,96]. The C-terminal of the 
yeast formin, Bni1 contains FH1 and FH2 domains. These domains are sufficient to 
nucleate actin filaments in vitro [97,98]. Interestingly, the FH1 and FH2 domains of 
Bni1 also cap the barbed end of actin filaments, decreasing but not blocking the rate of 
actin polymerization [99,100,101].  
In humans, there at least 15 members of the formin family of proteins but not all of 
them bind to small GTPases [92]. The interaction of mDia1 with RhoA relieves an 
autonomous inhibitory interaction making FH2 domain exposed, which then directly 
binds to barbed ends of actin filaments and functions as the actin polymerization 
machine. The FH1 domain promotes the interaction of the formin with the 
profilin/actin complex and brings it to the end of the actin filament to add new G-actin 
monomer to the barbed end of the filament [2]. 
 
ADF/Cofilin 
The ADF/Cofilin family of proteins in eukaryotic cells has a role in actin 
depolymerization. ADF (also known as destrin) was first identified in chick embryo 
brain tissue as an actin depolymerizing factor (ADF) [102]. These proteins are widely 
distributed among plants and animals tissues [102,103,104,105].  Cofilin binds to both 
G-actin as well as F-actin and enhances the rate of polymerization and 
depolymerization of actin filaments [106,107]. Cofilin engages itself in actin filament 
depolymerization by triggering monomeric actin disassociation from pointed ends 
[77,108,109]. Members of cofilin family of proteins depolymerize actin filaments via 
two mechanisms i.e., via severing and by accelerating the rate of depolymerization 
from pointed ends. When the ATP bound G-actin is abundantly available in the cell, 
cofilin enhances actin polymerization through its actin severing activity, by supplying 
the free barbed ends for continuous polymerization and nucleation via Arp2/3 
complex.  
Intriguingly, microinjecting the Arp2/3 nucleation blocking antibodies in cells, 
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significantly inhibited lamellipodia formation but does not inhibit free barbed ends 
suggesting that there might be an alternative mechanism that takes part in barbed end 
generation in vivo. Microinjection of antibody blocking cofilin in the same cell system 
inhibited barbed end generation suggesting that cofilin and Arp2/3 work in close 
cooperation in order to reorganize actin filaments. At the growing barbed ends, Arp 
2/3 complex binds to side of ATP loaded filamentous actin thereby triggering the 
nucleation of newly formed filamentous actin branch. On the other hand, cofilin 
mediated actin disassembly occurs after the Arp2/3 dissociates from the filamentous 
actin [110]. 
 
1.5.1c. Regulation of cell migration 
One of the fundamental and central aspect in the normal development of the 
multicellular organisms is the cell migration. For vital cellular processes for instance, the 
formation of tissue during embryonic development, wound repair and inflammatory 
immune responses, cells need to migrate in a direction to reach to a specific location 
within a body. Additionally, cell migration also occurs in human diseases such as 
metastasis, atherosclerosis etc. [111]. One of the characteristics necessary for cell 
migration is the protrusion at the cell front. Lamellipodia are rich in branched filaments 
of actin at cell front or leading edges. These sheet like extensions propel the cell body 
over the substratum. It is well documented that lamellipodia consist of branched actin 
filament networks formed via the actin-nucleating activity of Arp2/3 complex. Induced 
by growth factors, cytokines, hormones or extra cellular components, Rac1 is necessary 
for lamellipodia extensions and upon Rac1 inhibition cells fail to migrate [73,112]. 
Activation of Rac1 is brought about by tyrosine kinases, G-protein coupled receptors 
and mediated by phosphoinositide 3-kinase (PI3-Kinase). However, evidences indicate 
that the Arp2/3 complex is activated by Rac through its target IRSp53. Rac interacts 
with IRSp53, which in turn interacts through the SH3 domain with WAVE, which then 
binds to and activates the Arp2/3 complex. Inhibitors of PI3-kinase blocks Rac 
activation [113,114,115].  
Most migrating cells have small foci complex structures that are localized in the 
lamellipodia and are important for attachments of the lamellipodium to the 
extracellular matrix. Rac1 is required for focal adhesion complex assembly.  
Therefore, cells make new focal adhesion sites at the motile edges and degrade the 
attachments with ECM at the rear end. It is plausible that constant formation of new 
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interaction between integrins and the ECM at the motile edges of cells maintains 
activated Rac there. The cell migration speed is dependent on substrate composition, 
levels of RhoA, Rac1 and Cdc42 activation and it varies with the matrix composition.  
As the cell lamella moves forward, the focal complexes disassemble and in slowly 
migrating cells such as fibroblast they can mature into Rho-induced focal adhesions 
[116]. On the other hand, RhoA regulates the focal complex maturation into focal 
adhesions through its effector Dia1 and Rho-associated coiled coil-containing protein 
kinase (ROCK) [117,118,119,120]. 
Another aspect necessary for cell migration is the cell body contraction. Contraction of 
cell body and retraction at cell body rear are vital for cell movement. It is dependent on 
actomyosin contractility and can be controlled by RhoA [121]. For instance, upon RhoA 
inhibition, macrophages continue to extend, however the cell body fails to translocate 
[122,123]. It could be due to stress fiber contraction. Stress fibers are the major motor 
for cellular contraction. Stress fibers are formed of actin and myosin filaments. When 
the myosin fiber slides past the actin filament, it leads to the shortening of the stress 
fibers, providing the contractile force for cell motility [124,125]. The stress fibers attach 
to the integrin, transmembrane receptors via proteins complexes at the so-called focal 
adhesions. Rho acts via ROCK to affect the MLC by phosphorylating myosin light chain 
(MLC) and inhibiting MLC phosphatase. MLC phosphorylation is also regulated by 
MLC kinase (MLCK). The ultimate effect of MLC phosphorylation is cell contractility 
and stress fibre formation due to enhanced interaction between the actin filaments and 
MLC [126]. 
Additional aspect of the cell migration is the directional movement. Cells sense and 
respond to the guidance cues in their surroundings via filopodia. Filopodia are the 
finger-like protrusions present at the cell periphery. Cdc42 triggers filopodia formation 
and is required for directional sensing during chemotaxis in fibroblast cells as well as 
neurons [112,122,123,106]. By protruding out from cells into surrounding, receptors on 
filopodia detect changes in the extracellular signals that would then be transmitted back 
into cells.  
 
1.5.1d. Regulation of membrane trafficking 
Members of Rho family GTPases are well known to control many aspects of 
membrane trafficking, for instance the vesicle transport by endocytosis and exocytosis 
[127]. This cellular process is vital for the flow of material inside and outside a cell.  
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Rho GTPases in endocytic pathways  
Endocytosis via clathrin 
Numerous receptors involved in signal transduction pathways are internalized in cells 
by clathrin-coated pits. Upon internalization, these transmembrane receptors can be 
either directed for degradation by ending up in lysosomal compartments, which are 
highly acidic vesicles or they can be recycled back to cell surface via recycling 
endosomes [128]. These vital cellular processes are well controlled by actin 
cytoskeleton as observed in yeast [129]. However, latest results of Schmid et al., 2000, 
contradict this notion and discuss that the role of actin cytoskeleton may vary based on 
the cell type used and more importantly the experimental conditions [130]. For 
instance, in HeLa cells, overexpression of activated Rho or Rac blocks transferrin 
receptor endocytosis [131]. Additionally, as discussed by Apodaca G et al., 2000 
activated Rac blocks endocytosis from both basolateral and apical membranes of 
epithelial cells that are highly polarized [132,133]. Intriguingly, Rac1 GTPase can bind 
with synaptojanin 2, a polyphosphoinositide phosphatase involved in clathrin-coated 
vesicles uncoating [134]. By recruiting synaptojanin 2 at the plasma membrane, Rac1 
act specifically by inhibiting the coated pit formation thereby blocking endocytosis. This 
activity of Rac explains its role in extending the lifespan of activated receptors at the 
plasma membrane [135]. 
On the other hand, Rho GTPases also affect certain stages of endosomal trafficking (i.e., 
stages such as: directing endosome vesicles either to lysosomes or recycling to plasma 
membrane) [136]. For instance, endogenous and myc-tagged RhoB was shown to 
localize to endosome compartments and have a key role in endosome trafficking [137]. 
Ectopic expression of GFP-tagged RhoB localizes in the perinuclear compartment in 
live cells [72]. However, it is plausible that GFP-tag could lead to mislocalization of 
RhoB due to protein folding. At the endosome vesicle, RhoB targets serine/threonine 
kinase, PRK1 to slow down trafficking of the endocytosed EGF receptor from 
endosome vesicles to pre-lysosomal compartment [132,138]. Another member of Rho 
family GTPases, RhoD also localizes to endosome. Ectopic expression of activated 
RhoD/G26V changes early endosomal distribution and motility [139]. Ectopic 
expression of activated or dominant negative Cdc42 also affect endosome recycling of 
polarized MDCK cells. However, it is unclear whether the effect is related to actin 
cytoskeleton [140]. 
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Pinocytosis 
Pinocytosis is a form of endocytosis whereby extracellular fluid is internalized 
resulting in the formation of cell membrane invagination. Experimentally, it can be 
studied by tracing cellular uptake of fluorescent molecules from the medium. This 
form of endocytosis is necessary for a cell in order to uptake nutrients that are 
necessary for cell homeostasis such cell growth and cell motility. Active variant of Rac 
has been shown to stimulate pinocytosis. Interestingly, PAK1, a Rac/Cdc42 target is 
needed for macropinosome formation upon growth factor stimulation [141]. A 
controversial model has been put forth discussing Rac-stimulated pinocytosis enhances 
the membrane ruffling and these ruffles fold back forming membrane bound vesicles 
[142]. Subsequently, this model was accepted since it clearly demonstrated that 
immature dendritic cells while sampling their surroundings for antigens do pinocytose 
via membrane ruffling [143]. 
 
Phagocytosis 
Another form of endocytosis is called phagocytosis. It results by engulfing large 
particles (i.e., bacteria, virus etc). This form of endocytosis is usually carried out by 
mature macrophages, neutrophiles, and phagocytes cells to clear out the antigens. The 
mechanism by which phagocytic cells engulf large particles depends on the receptor 
type present on the phagocytic cell surface. For instance, particles coated with 
antibody are taken into the cell via Fc gamma receptor [4]. This involves the actin 
polymerization via Arp2/3 complex mediated by Cdc42/Rac [4]. However, there are 
no real evidences to indicate that Cdc42/Rac are involved in driving movement of 
phagosome away from cell membrane although it has been suggested that PI3-K 
perhaps acts at later steps to regulate endocytosis and not Cdc42/Rac mediated actin 
polymerization [135]. 
 
1.6 Rho GTPases in disease development 
1.6.1a. In cancer 
After the identification of RhoA, it became apparent that RhoA was not acting as an 
oncogene in the same sense as Ras. With an exception of RhoH, there are no mutations 
identified in the genes encoding Rho GTPases in human cancer. Instead, the expression 
of Rho GTPases seems to be down regulated in cancer particularly in conditions such as 
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cancer cell migration, tumor invasion and metastasis. For instance, RhoH (also known as 
TTF) is upregulated in non-Hodgkin’s lymphomas, multiple myeloma, as well as large 
cell lymphoma with the mutations in the 5’ UTR region, that indicates the direct role of 
RhoH/TTF in cancer although precise mechanism is still unclear [144]. Experimentally, 
tumor derived cell lines and mouse models clearly advocate that the protein levels of  
master regulators of Rho GTPases (i.e., RhoGEFs and RhoGAPs) have a direct bearing 
on the initiation as well as tumor progression [144]. Deregulated RhoGEFs and GAPs 
signaling lead to aggressive cell migration, invasion and metastasis of various tumor cell 
types caused by variations in the levels of Rho proteins and untimely activation [145].  
Altered Rho signaling particularly impacts the cellular scaffold or cytoskeleton whose 
organization and reorganization supports the motility of cancer cells during the invasive 
growth [146]. Nowadays, it is generally accepted that Rho GTPases are frequently 
upregulated in many human cancers, summarized in the Table 2 [144]. The variation in 
the expression can occur at mRNA or protein level. For instance, experimentally when 
malignant breast tissue samples were compared to the normal breast tissue samples, it 
was observed that the levels of Rac1 protein were elevated much higher in the malignant 
breast tissue compared to the normal breast tissue, indicating Rac1 triggers breast tumor 
formation in vivo [147,148]. In addition upregulation of Rac1b, a splice variant of Rac1 
triggers cellular transformation in breast and colon carcinoma cells. In vitro studies in 
mouse fibroblast cells suggest that Rac1b signaling might be involved in cell survival 
signals via NFκB [149]. Contrarily, downregulation of Rac1 leads to embryonic lethality 
in vivo [150]. 
 Studies in the mouse leukaemia model have ascribed important roles of Rac3 in cancer 
progression [151]. In that study, the mice deficient of Rac3 were observed safe against 
lymphoblast leukaemia induced by crossing with mice expressing a fusion oncogene, 
BCR-ABL. This suggests that intervention with Rac3 function can be explored as 
therapeutic target for B-cell lymphomas or blood cancers [151,152]. 
Altered expression levels of regulators of Rho GTPases also cause cancer development 
by resulting in the deregulated signals downstream of Rho proteins. For instance, 
deprivation of Tiam1, a RacGEF, maintains E-cadherin based cell-cell adhesion that 
leads to epithelial-to-mesenchymal transition [153,154]. The studies carried out in 
mouse tumor models suggest that the lack of Tiam1 enhances invasion of Ras-induced 
epithelial skin tumors as well as β-catenin/TCF-induced intestinal tumors [155,156]. 
Moreover, point mutations in the N-terminal of PH domain of Tiam1, drastically affects 
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its localization and it has been observed in approximately 10% of samples affected by 
human renal-cell carcinoma samples [157]. The levels of Tiam1 protein have also been 
observed to be upregulated in human prostate carcinomas [158].  
 
Rho GTPase Variation Cancer/Tumor type 
RhoA Upregulation Breast, HNSCC*, colon, lung, gastric, bladder 
and testicular cancer 
RhoB Upregulation 
or downregulation 
Breast (upregulation), lung and HNSCC* 
(downregulation) 
RhoC Upregulation Breast and metastatic gastric cancer 
(inflammatory), pancreatic ductal 
adenocarcinoma, bladder cancer, NSCLC* 
and HNSCC 
Rac1 Upregulation Breast, gastric and testicular cancer OSCC* 
Rac1b Alternative splicing Breast and colon cancer 
Rac2 Upregulation HNSCC* 
Rac3 Hyperactivation  
or upregulation 
Breast cancer 
RhoG Upregulation Breast cancer 
Cdc42 Upregulation Breast and testicular cancer 
RhoH/TTF Upregulation  
and mutations 
(5’UTR) 
Non-Hodgkin’s lymphoma and multiple 
myeloma (upregulation) and diffuse large B-
cell lymphoma (mutation) 
RhoE/Rnd3 Upregulation  
and downregulation 
NSCLC (upregulation) and prostate cancer 
cancer (downregulation) 
RHO GTPASE REGULATORS 
Tiam1 Point mutation Renal-cell carcinoma, prostate carcinoma and 
breast cancer (upregulation) 
LARG Fusion to MLL Acute Myleiod Leukemia (AML) 
DOCK 180-
ELMO1 
Upregulation Glioma 
Vav1 Upregulation Pancreatic adenocarcinoma, neuroblastoma 
β-PIX Upregulation Breast cancer 
RhoGDIα Downregulation Invasive ovarian (upregulation) and breast 
 
Table 2. The mutations in Rho GTPases and their regulators with associated 
cancer types [adapted from source 144]. 
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Upregulation of GDIs has also been well documented to occur during the different 
stages of cancer progression. RhoGDI1 or RhoGDIα has been observed to be 
upregulated in colorectal and ovarian cancers [159,160]. Contrarily, dowregulation of 
GDI2 have been observed to promote development of muscle invasive bladder cancer 
[161]. The RhoGAPs constitute another group of key regulators that contributes to 
cancer progression. Genomic deletion of DLC-1, a GAP for RhoA and Cdc42 has been 
found in primary tumours [162]. Deletion of DLC-2 expression has also been found in 
hepatocellular carcinomas [162,163]. Deletion or downregulation of these GAPs lead to 
enhanced activation of Rho GTPases and their downstream signaling pathways during 
cancer progression. The examples mentioned above, it is still unclear about the 
specificity of most of the regulators of Rho proteins in vivo perhaps uncontrolled signals 
emanating via Rho GTPases are sufficient for the contribution of tumor progression.  
 
1.6.1b. In neurodegenerative disorders 
In a developing and well-developed nervous system, Rho GTPases have an important 
role in neuronal morphogenesis and dendritic plasticity by regulating the actin 
cytoskeleton at various stages. The Rac1 and Cdc42 have been well studied for their 
roles to promote the growth and dendritic stability whereas RhoA has been shown to 
inhibit this growth [164]. Many GEFs and GAPs are expressed in the nervous system 
making them likely to be involved in the specific Rho GTPases mediated signaling 
pathways leading to the neuronal processes. For instance, neuropathological disorder, X-
chromosome linked mental retardation (MRX) impairs the cognitive function in the 
individuals suffering from this disease, which affects 1 in 500 males representing 25% 
of genetically, manifested cases of mental retardation [5]. Upon closer histological 
inspection of the brain structure it was observed that patients suffering from MRX 
disease had increased size of hippocampus and certain cerebellar ventricles. In contrast, 
the cerebral cortex appeared reduce in size compared to the unaffected control tissue 
samples [165,166]. Additionally, microscopic examination showed thinner and 
stretched dendritic spines in the affected regions of patients suffering from mental 
retardation (MR). A closer look at the synaptic contacts revealed that this region had 
immature dendritic spines cells [167,168]. Synapses at the spines are thought to 
transmit the majority of functionally excited synaptic communication [169]. It was via 
positional cloning that ten genes related to mental retardation were identified giving an 
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insight into mutational basis for study of genetics and biochemistry involved in mental 
retardation (Table 3).  
Out of the genes/proteins enlisted Table 3, three genes/proteins namely, oligophrenin-
1, PAK and PIX/Cool-2/ARHGEF6 are directly involved in Rho GTPases mediated 
signaling pathways observed in neurons [170]. Another example of the involvement of 
Rho GTPase in neurodegenerative disorder is mutation in the RhoGEF, alsin, which 
causes the Amyotrophic lateral sclerosis (ALS) [171]. ALS causes a very life-
threatening disorder in which motor neurons degenerate with time. It has an important 
role in neurodegenerative disease [171]. Another key molecule is the Intersectin, for 
which the gene is located on chromosome 21 in humans and has been studied for its 
role in neuronal defect, Down syndrome by impairing Rho GTPase mediated signaling 
using mice model [172].  
Apart from the neurodegenerative disorders discussed above, alterations of 
mitochondrial dynamics and fusion also have been reported to link human neurological 
diseases affecting a specific area in the brain and nervous system, thereby highlighting 
the important role of mitochondrial function in maintaining healthy neurons [173]. 
Interestingly, Miro GTPases are well known to regulate mitochondrial motility along 
the microtubules in order to migrate to distinct location intracellularly. There is a 
substantial amount of genetic and chemical evidence indicating the involvement of 
mitochondria in Parkinson’s disease (PD), which is the second most common 
neurodegenerative disorder in humans, in which there is a continuous loss of 
dopaminergic neurons in the substantia nigra, symptoms observed are resting tremor, 
rigidity, bradykinesia and a unsteady gait (Figure 9) [173]. 
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Figure 9. The neurodegenerative disorders related to mitochondrial dynamics 
defects [adapted from source 173]. 
 
Two genes have been identified in patients suffering from Parkinson’s disease, Pink1 
and Parkin; both have been shown to have a key role in mitochondrial integrity [174].  
Pink1 is a serine/threonine kinase and has an N-terminal sequence that targets 
mitochondria. It localizes both within mitochondria as well as in cytosol. On the other 
hand, Parkin is a cytosolic E3 ubiquitin ligase with two RING fingers, cysteine and 
histidine-containing protein motifs that coordinate zinc ions. The studies with Pink1 
and parkin in mammals have yielded less success due to the fact that mouse knockouts 
displayed very little phenotypical changes and did not show the common symptoms of 
Parkinson’s disease [173,175,176,177]. Moreover, additional studies indicate that loss 
of Pink1 can result in morphological abnormalities in the mitochondria [178].  
Deficiency of Pink1 in human dopaminergic neurons or primary mouse neuronal 
cultures leads to reduced viability accompanied by abnormal and enlarged 
mitochondria [178]. Experiments with Pink1 double knockout mice (-/-) did not reveal 
any ultrastructure alterations of mitochondria, except the fact that the mitochondria 
appeared somewhat larger. Similar results were also observed in the cell line, COS7 
where the knockdown of Pink1 also showed increased mitochondrial size through 
tubulation [173,179].  
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Genes/Proteins Functions Clinical 
symptoms 
Spine/synapse 
phenotypes 
Oligophrenin-1 Rho GAP for 
RhoA, Rac1 and 
Cdc42 
MR*, cerebellar 
hypoplasia, 
epilepsy 
Spine length 
reduced, 
reduction in 
mature spines 
PAK3 Serine/threonine 
kinase, effector 
of Rac1/Cdc42 
MR* Abnormal 
elongated spines, 
decrease in 
mature synapses 
αPIX/Cool-2 
ARHGEF6 
Rho family 
GEF for 
Rac1/Cdc42, 
interact with 
PAK 
MR* Reduction in 
large mushroom 
type spines 
FMRP RNA binding 
protein (Rac1), 
interacts with 
CYFIP, 
downstream of 
Rac1 
MR*, 
macrocephaly, 
long face, long 
ears, 
macroorchidism 
Long and 
irregular 
dendritic spines 
MEGAP, WRP, 
srGAP3 
Rho family 
GAP for 
Rac/Cdc42 
Macrocephaly, 
growth failure, 
heart and renal 
defects, 
hypotonia and 
facial 
abnormalities 
Loss of filipodia 
and dendritic 
spines 
LIMK1 Ser/Thr kinase, 
downstream of 
Rac1/Cdc42 
Williams 
syndrome 
Decreased spine 
head size and 
thicker spine 
necks 
Alsin GEF for Rac1, 
Rab5 and Ran 
Motor neuron 
degeneration 
Reduced axon 
growth, 
increased cell 
death 
  
Table 3. Shows different Rho GTPases, their regulators and the clinical 
manifestations when mutated [adapted from source 170]. 
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1.7 Rho GTPases as therapeutic targets 
From basic to clinical research, there are considerable evidences suggesting that the 
pathways downstream of Rho GTPases have role in disease for instance cancer 
development and progression [180]. Consequently, there has been a profound interest to 
target specific Rho proteins involved in Rho GTPase-dependent signaling pathways in 
malignant transformation as potential therapeutic targets. Therefore, varieties of effector 
protein inhibitors have emerged. However, not all of these inhibitors have entered 
clinical trials. Nevertheless, it is promising to explore their nature as a drug against 
different types of tumors [180].  
Approximately, 80 GEFs for Rho GTPases are known and their modes of action have 
been well studied [28,181]. Due to the key roles of these proteins in the activation of a 
specific Rho GTPase, they were considered targets for drug development (Table 4) 
[180]. For instance, RhoG, Rac and RhoA are activated by the RhoGEF Trio and an 
alternate splice variant, Tgat that are considered druggable. In addition, LARG 
(Leukemia-associated RhoGEF) activates RhoA/B/C have also been considered as a 
therapeutic target [182,183,184,185]. Trio is upregulated in breast and glioblastoma 
cancers and it is associated with poor prognostic outcome. Tgat on the other hand is 
capable of transforming NIH 3T3 cells by virtue of the loss of contact inhibition, 
anchorage independent growth, tumorigenicity in nude mice and increased invasiveness. 
Since both Trio and Tgat GEFs are involved in catalyzing the exchange of GDP to GTP, 
it makes them ideal candidate for drug development by developing an inhibitor molecule 
that could bind the GTP pocket thereby inactivating the signaling cascade downsteam of 
Rho GTPases (Figure 10) [145,186].  
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Class Inhibitors Applications    
  In vitro Cells In vivo Clinic 
Rho GEFs 
Trio/Tgat TRIAPα 
(bacterial toxin) 
√    
 TRIPα √ √   
 TRIPE32G √ √   
 ITX3 √ √   
LARG  √    
Tiam NSC23766 √ √   
Rho GTPases 
Rho C-3 exoenzyme 
C3-05/BA-210 
√ √  
√ 
 
√ 
Rac1 EHT1864 √ √   
      
Rho/Rac MLS000532223 √ √   
Cdc42 MLS000573151 √ √   
IsoPrenylation 
inhibitors 
     
GGTase Statins  √  Widespread 
use in clinic 
to control 
cholesterol 
levels 
GGTase/FTase AZD3409    √ 
 26b √    
  
Table 4. Rho GTPases activators and their functional inhibitors [adapted from source 
180]. 
 
In addition to a central role in controlling actin-related mechanisms, Rho GTPases are 
also involved in virtually all the cellular processes. This makes them a key ideal targets 
for drug development. For instance, Rho GTPases are important in cell cycle progression 
through G1 phase of cell cycle by regulating the expression of cyclin D1 and cyclin-
dependent kinase (CDKs) inhibitors p21 and p27 [187,188,189,190]. Intriguingly, very 
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few compounds have been developed till date that target Rho GTPases and their 
effectors. Nevertheless, many strategies have been developed to inhibit interactions 
between GTPases and cognate GEFs in order to block Rho signaling activation (Table 4) 
[191].  
Alternatively, another way of inhibiting GTPase function is by displacing nucleotide 
binding, nevertheless, questions remain regarding the specificity of this approach [192]. 
Another approach that could be explored is inhibiting C-terminal modification of Rho 
GTPases that are necessary for anchoring with the cell membrane. This can be achieved 
by inhibiting C-terminal modifying enzymes or by limiting the essential supply of lipid 
for these modifications (for example, isoprenylation), which is possible by using a Statin 
class of drugs (Table 4) [193]. Statins target Rho function by interfering with the 
attachment of lipid moieties at their C-terminus. Since, C-terminus lipid modifications are 
important for correct intracellular localization of Rho GTPases. Statins class of 
compounds include HMG-CoA reductase inhibitors, which deplete the cellular pool of 
isoprene precursors as well as prenyl transferase inhibitors (i.e., farnesyltransferase and 
geranylgeranyl transferase inhibitors (GGTI) [194,195,196].  
In conclusion, the examples metioned above discuss the ability of each Rho GTPase 
member to trigger the activation of many cellular pathways, making them the likely 
targets for therapy since they might be a part of critical signaling hubs [197].  
Nonetheless, blocking Rho GTPases could affect multiple signaling pathways that might 
most likely result in dose-limiting toxicities.  There are other promising ways for instance 
targeting kinases by inhibitors (Table 5). The first Rho effector to be targeted as a 
therapeutic agent was Rho-associated kinase (ROCK1/2) by Y-27632 inhibitor. This 
fuelled a considerable interest of pharmaceutical companies to invest into drug 
development using Y-27632 inhibitor (Table 5). The ROCK isoform inhibitors are 
currently under investigation for many drug discovery programs [197,198]. Using 
selective inhibitors will allow analyzing biological function [198]. The use of 
Chelerythrine chloride against MRCK has been shown to be similar to ROCK in 
inhibiting cancer invasion. Inhibition of p-21activated kinases (PAKs) activity has been 
tested and inhibitor have been developed by using small molecule group 1-vs 2- selective 
inhibitors [199].  For future studies, these inhibitors will be useful to study the role of 
PAKs in disease such as cancer (Table 5) [199].                                     
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Kinases Inhibitors  Applications   
  In vitro Cells In vivo Clinic 
ROCK1/2 Y-27632 
Y-30141 
Y-30946 
Fasudi(HA-
1077)/Hydro 
xylfasudil 
H-1152P 
Lead compound 
14A 
Isoquinoline-based 
compound 35 
GSK269962A 
SB-7720770-B 
√ 
 
 
 
 
 
√ 
√ 
 
 
 
 
 
√ 
√ 
 
 
 
 
 
√ 
√ 
 
 
 
 
 
√ 
 
√ 
 
 
√ 
 
√ 
 
 
 
 
√ 
ROCK2 SLx-2119 
Indazole piperazine 
Indazole 
piperidine 
 
√ 
√   
LIMK1/2 BMS compound 3 
Pyrrolopyrimidine 
Compounds 
 
 
√ 
√ 
√  
√ 
 
MRCKα/β Chelerythrine 
chloride 
√ √   
PAK4,5,6 
and 1 
PF-3758309 √ √ √  
PAK IPA-3 √ √   
    
Table 5.  Kinases inhibitors downstream of Rho GTPases signaling [adapted from 
source 199] 
                       
 Figure 10. The druggable target sites in the Rho GTP/GDP cycle ($). 
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In conclusion, rapid advances have been made in trying to develop and optimize novel 
inhibitors targeting different Rho GTPases and their downstream effectors. So far, none 
of these inhibitors for Rho GTPases has been used as a standard therapy in patients 
suffering from diseases for instance, cancer. Nevertheless, their anti-tumor activities in 
vivo substantiate their future development and hint that they can be used alone or in 
combination with other cytotoxic drugs [180]. The day first Rho signaling inhibitor is 
approved and tested on patients suffering from disease like cancer or Parkinson’s 
disease, it will be a milestone for researchers [180]. 
 
1.8 The RhoD and Rif subfamily of GTPases 
The Rho GTPases comprise of 20 members. The RhoD and Rif proteins are less studied 
members of classical Rho subfamily of GTPases (Figure 3). From the evolutionary point 
of view, RhoD/Rif-like proteins appeared first in tunicates (urochordatas) like sea squirts 
[139,200]. Subsequently, RhoD precursor protein duplication resulted in the RhoD 
protein (in therians). Evolutionarily compared to Rif, RhoD evolved much later and is 
expressed only in mammals [201]. Both RhoD and Rif play a pivotal part in the actin 
dynamics regulation. Additionally, RhoD have also been studied in relation to their role 
in endosome vesicle transport [139,202,203]. The RhoD and Rif are expressed in the 
subset of tissues and unlike Cdc42, Rac1 and RhoA that are expressed in virtually all 
cell types [200]. 
 
1.8.1a. Domain organization and regulation 
 
 
Figure 11. The location of RhoD and Rif. RhoD and Rif are localized on chromosome 
numbers 11 and 12 in humans (adapted from Genecards). 
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The RhoD and Rif genes are located on chromosome numbers 11(11q14.3) and 
12(12q24.31)(Figure 11) [201]. Like most classical Rho GTPases, the RhoD and Rif 
proteins contain GTP-binding domain and a C-terminal CAAX box. It is considered to 
be post-translationally farnesylated by geranyl-geranylation; however this has not 
actually been clearly demonstrated. A recent report suggests that RhoD and Rif possess 
an elevated intrinsic exchange activity [204]. In this regard, they resemble the atypical 
Rho members Wrch-1 and the activated Rac1 splice-variant Rac1b. This suggests that 
RhoD and Rif also act as atypical Rho GTPases, something that also indicate that they 
are not likely to be regulated by GEFs and GAPs, rather by other means, such as post-
translational modifications. Once docked and anchored at the plasma membrane, the 
RhoD is activated and triggers physiological response to activating signals. 
Fundamentally, RhoD and Rif share high sequence similarity and domain organization, 
only noticeable difference being the presence of an extension of few amino acids at the 
N-terminal of Rif GTPase. However, no particular function has been ascribed to this 
extension (Figure 12) [201].  
 
Figure 12. Schematic representation of domain organization of RhoD and Rif 
[adapted from source 201].                     
 
 
1.8.1b. RhoD/Rif in the regulation of actin cytoskeleton dynamics 
The present knowledge and understanding regarding the role of RhoD/Rif in the 
regulation of actin cytoskeletal dynamics emanates from the experiments where different 
variants of RhoD/Rif (i.e., wild type, constitutively active and dominant negative) were 
overexpressed in different cell types. For instance, overexpression of the active variants 
of RhoD and Rif in PAE/PDGFRβ or HeLa cells changed the cell morphology observed 
as thin and long protrusions of filamentous actin appearing either from the dorsal or the 
peripheral sides of cells. Similarly, morphological changes have also been observed in 
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cell lines such as NIH3T3, SHSY5Y and PC-12 [205].  These long and thin filopodia are 
highly dynamic structures arising from the cells particularly from the leading edges and 
are rich in linear bundles of filamentous actin cross-linked to each other by actin-binding 
proteins such as fascin. Filopodia are best known for their important roles in cell-cell 
interaction, sensing and migration [206,207,208,209,210]. 
  Additionally, RhoD and Rif mediated filopodia’s are of 20-40µm in length compared to 
conventional filopodia, which are of approximately 8-15 µm in length [139,211,212]. 
The complete understanding of how RhoD is involved in filamentous actin 
polymerization or filopodia formation has not been completely achieved [212,213]. 
However, in paper I, we suggest that via the effectors of RhoD, WASP-homolog 
associated with actin, membrane and microtubules, WHAMM and Filamin-A (FLNa) 
binding protein, FILIP1 involved in actin polymerization [214]. Interestingly, out of 
these two-RhoD binding proteins, WHAMM binds to Arp2/3 complex via its c-terminal 
WCA domain and FILIP1 binds FLNa. Both these proteins act downstream of RhoD in 
regulating the actin polymerization and cytoskeletal dynamics thereby regulating the 
polymerization of filamentous actin [214].   
 
1.8.1c. RhoD in the regulation of vesicle trafficking  
Studies by Gasman et al., 2003 observed another role of RhoD in regulating the vesicle 
trafficking or endocytosis [203]. Endosome vesicles are very dynamic structures. 
These endocytic vesicles need a close cooperation of cytoskeleton (i.e., actin and 
microtubules) to deliver cargo [202]. For instance, close association of microtubule, 
microtubule motor proteins and filamentous actin are needed for the correct 
positioning, internalization and dispatching cargo from early to late/recycling 
endocytic vesicles within a cell [201]. Intriguingly, members of small GTPases, Rho 
and Rab subfamilies are involved in regulating endosome motility. For instance, Rac1, 
RhoA have a key role in receptor uptake. Rab5 GTPase has an important role in 
stimulating the migration of the early endosome vesicles on the microtubules through 
kinesin-like motor proteins [201,203]. Also, RhoB has been shown to co-ordinate 
transport of cargo from late endosome vesicle to lysosomes [138].  
Vesicle trafficking needs additional functionally specific proteins known as effector 
proteins, such as DRFs, which help the members of Rho and Rab GTPases to carry out 
vesicle trafficking in a well coordinated manner [139]. Examples of effector proteins 
include, mDia1 that binds to RhoA, mDia2 to Cdc42 and RhoA, FHOS, FRL binds to 
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Rac1 [203,215]. 
 For shuttling a cargo to a short distance intracellularly, endosomes use actin filaments.   
Conversely, for a long distance transport endosome vesicles hop on to microtubules. 
This mechanism has been studied by destroying the microtubule network using 
microtubule depolymerization compounds such as Nocodazole, Vincristine and 
Colchicine in cells. Endosome motility was impaired and the endosome vesicles were 
localized to the cell periphery [202]. Ectopic expression of RhoD, blocks Rab5-
dependent effect on early endosomes. Moreover, RhoD induces spherical, scattered 
and small endosome vesicles compared to Rab5 endosomes. With the identification of 
RhoD effector protein hDia2C, a great deal of interest arouse in how RhoD via hDia2C 
regulates early endosome motility. Subsequent studies found that hDia2C promotes the 
alignment of early endosomes on the filamentous actin tracks. However, RhoD-
mediated inhibition of endosome shuttling was dependent on Src activity and was 
reverted by an actin-depolymerizing drug, cytochalasin D [203]. This suggests a 
mechanism by which RhoD blocks endosome movement in a Src-dependent but actin-
independent manner.  Fundamentally, the assumption of this study was based on an 
observation describing the pathway in which RhoD was needed for the c-Src activation 
on endosomes via hDia2C [203]. 
Another example is that of Src family kinase members, Fyn that has been observed to 
localize to vesicles positive for RhoD [203].  RhoD directs Fyn to the cell membrane 
via the post-translational modification on Fyn (i.e., palmitoylation). Collectively, the 
observation regarding the localization of RhoD and its role in early endosome motility, 
suggests that RhoD can control the localization of Src family kinases and thereby 
regulate the early endosome motility. 
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2. AIMS  
The work in this thesis highlights the role of RhoD, a less studied member of the Rho 
subfamily of GTPases. The overall aim was to elucidate the biological function of 
RhoD, and RhoD downstream signaling pathways. At the start of the thesis work, novel 
RhoD interactors via yeast two-hybrid screening were identified namely: FILIP1, 
WHAMM, Rabankyrin-5 and ZIP kinase.  Furthermore, I wanted to study their potential 
role in the regulation of actin filament system, cell adhesion, cell migration, protein and 
tyrosine kinase receptor trafficking. 
The specific aims of this thesis are:  
• To elucidate the role of RhoD, via its binding partners WHAMM and FILIP1 in 
the regulation of actin cytoskeletal dynamics, cell adhesion and migration 
(Paper I). 
• To clarify the role of RhoD, via its effectors, WHAMM and FILIP1 in the 
regulation of protein transport from ER to cell membrane via Golgi (Paper II). 
• To determine the role of RhoD, via the Rab5 effector Rabankyrin-5 in receptor 
tyrosine kinases trafficking (Paper III). 
• To dissect the mechanism by which the interaction of RhoD and ZIPk regulates 
the actin filament assembly and focal adhesion dynamics (Paper IV). 
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3. HIGHLIGHTS OF METHODS 
Yeast two-hybrid screen 
The Saccharomyces cerevisiae strain Y190 (genotype; MATa, gal4-542, gal80-538, 
his3, trp1-901, ade2-101, ura3-52, leu2-3, 112, URA3::GAL1-LacZ, Lys2::GAL1-
HIS3cyhr) was transformed with a cDNA that encodes human RhoD/G26V fused to the 
GAL4 DNA-binding domain (GAL4DB) in the pYTH9 vector [216]. This RhoD 
construct harbored cysteine-to-serine mutations in its CAAX box, since we reasoned that 
this would facilitate the nuclear translocation of RhoD during the screening procedure. 
This GAL4DB-RhoD/G26V–expressing yeast strain was used to screen a cDNA library 
from human mammary glands. 
Protein production and GST pull-down assays 
GST-tagged fragments of FILIP1, WHAMM, Rabankyrin-5, RhoD, or GST alone 
were expressed in Escherichia coli and purified on glutathione-Sepharose beads. The 
pull-down assays were performed described previously [217]. 
Cell culture and transfection 
Human embryonic kidney 293T (HEK293T) cells, BJ human foreskin fibroblasts 
stably transfected with hTERT, and SV40 large T antigen (BJ/SV40T) cells, and green 
monkey COS-1 cells were cultured in DMEM supplemented with 10% (vol./vol.) fetal 
bovine serum (FBS) and 1% (vol/vol) penicillin–streptomycin. Porcine aortic 
endothelial cells stably transfected with the human platelet-derived growth factor β-
receptor (PAE/PDGFRβ cells) were cultured in HAM’s F12 medium supplemented 
with 10% (vol./vol.) FBS and 1% (vol./vol.) penicillin–streptomycin. All cell lines 
were cultured at 37°C in an atmosphere of 5% CO2. The cells were transfected using 
Lipofectamine or JetPEI reagents, according to the protocols provided by the 
manufacturers.  
Immunoprecipitation 
For immunoprecipitation, the transiently transfected cells were lysed on ice in Triton 
X-100 lysis buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 1% Triton X-100, 10% 
glycerol, 5 mM EDTA, 1% aprotinin) 48 h post-transfection. The cell lysates were 
centrifuged for 15 min at 4°C, and the supernatants were incubated with the primary 
antibodies for 1 h at 4°C, after which the immunoprecipitates were collected on protein 
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G-Sepharose for 1 h at 4°C. The beads were washed three times with Triton X-100 
lysis buffer and subjected to SDS–PAGE, and the proteins were subsequently 
transferred onto nitrocellulose. Western blotting analyses were performed with the 
antibodies as specified in the figure legends; this was followed by horseradish 
peroxidase–conjugated anti-mouse or anti-rabbit antibodies. The proteins on the 
Western blots were revealed using Luminol immunoblotting reagent. 
 
RNAi work 
Knockdown of RhoD, WHAMM, FILIP1 or Rabankyrin-5 expression was induced by 
transfecting the BJ/SV40T cells with RhoD-directed siRNAs or with WHAMM-
directed siRNAs, RhoD siRNA, or a nontargeting siRNA using the SilentFect 
transfection reagent. The cells were incubated for 48 h posttransfection before being 
processed for the various assays. 
Antibodies, reagents, and constructs 
All the antibodies, constructs and reagents used in investigating the specific aims 
mentioned are documented in the articles/manuscripts enclosed. 
Immunocytochemistry 
The cells were seeded onto coverslips in six-well plates, fixed in 3% 
paraformaldehyde in phosphate-buffered saline (PBS) for 25 min at 37ºC, and then 
washed with PBS. The cells were permeabilized in 0.2% Triton X-100 in PBS for 5 
min, washed with PBS, and blocked in 5% FBS in PBS for 30 min at room temperature. 
The primary and secondary antibodies were diluted in PBS containing 5% FBS. The 
cells were incubated with the primary antibodies and secondary antibodies for 1 h each, 
with washes in PBS between the incubations. The coverslips were then mounted on 
microscopy slides using Fluoromount-G, photographed using a Zeiss AxioCAM MRm 
digital camera connected to a Zeiss AxioVert 40 CFL microscope, and processed with 
the AxioVision software. The cellular effects induced by ectopic expression were 
determined by microscopy analysis.  
Wound closure assay 
For the wound closure assay, cells were seeded in six-well plates. The following day, 
siRNAs were transfected using SilentFect. The cells reached confluency over the next 
48 h, and wounds were made in the confluent monolayers with a Gilson P200 pipette 
  
37 
plastic tip. Two to three spots along the wound were marked with a pen under the 
plate. The wounded areas were photographed directly after the wounding (0 h) and 
again after 20 h with a Zeiss AxioVert 40 CFL microscope using a 10× objective. The 
cells that had moved into the wounded areas were counted on the photographs. The 
field of view was 0.603 mm2. The experiment was repeated five times and data from 
two to three wounds were analyzed for each condition. 
 
Cell viability assay 
Cell survival was determined by the calcein AM viability assay according to the 
protocol provided by the manufacturer. Cells were washed three times with PBS and 
then treated with 1 mM calcein AM in PBS for 50 min at room temperature; this was 
followed by analysis of the fluorescence intensity at excitation 490 and emission 520 
on a fluorescence plate reader. 
 
Cell adhesion assay 
For the adhesion assay, cells were seeded in six-well plates and, the following day, the 
cells were transfected with siRNAs as described above. After 48 h, the cells were 
trypsinized and seeded on coverslips precoated with serum. The cells were allowed to 
adhere for 30 min, 1 h, or 2 h. The cells were then washed with PBS to remove 
nonadhered cells and fixed in 3% paraformaldehyde for 25 min. The coverslips were 
mounted and photographed with a Zeiss AxioVert 40 CFL microscope using a 10× 
objective. Cells attaching to the coverslips under the different conditions were counted 
on the photographs. The data shown represent quantifications from 5 to 10 random 
sites at the coverslips and were normalized to the amount of cells attaching at the 
initial time point. 
 
Golgi transport assay 
In essence, the original protocol from Presley et al. was used [218]. In brief, cells were 
transfected with EGFP-VSV-G alone or together with FILIP1, WHAMM or Rho 
GTPases. In those cases where the cells had been transfected with siRNAs, the cells 
were transfected with EGFP-VSV-G after 24 hours. The cells were kept at 40°C after 
the transfection and the transport of EGFP-VSV-G from the ER to the cell membrane 
via the Golgi complex was initiated by a transfer of the cells to 32°C. 
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4. RESULTS AND DISCUSSION 
In brief 
To decipher the signaling pathways downstream of RhoD, a yeast-two hybrid screening 
was performed. We used the constitutively active RhoD/G26V mutant fused to the DNA-
binding domain of GAL4 as bait to screen a human mammary gland cDNA library fused to 
the GAL4 activation domain. We confirmed the interaction of RhoD with its potential 
binding partners by co-immunopreciptation. We also mapped the precise domain of 
interaction between RhoD and its binding partners. Subsequently, their functional roles in 
cellular signaling context were investigated using different tools and strategies (Papers I, 
II, III, IV).  Herein, I will discuss the results that we have achieved. 
 
Serial no. RhoD interacting protein Cellular function 
1. FILIP1 Filamin A-interacting protein involved 
in cytoskeletal function. 
2. Rabankyrin-5 Rab5 effector. Endocytic protein 
3. Death-associated protein 
Kinase 3 (DAPK3/ZIPk) 
Cytoskeletal regulation during apoptosis 
    
Table 6. Shows RhoD binding proteins emanated from the yeast-two hybrid 
screening. 
 
To elucidate the role of RhoD, via its binding partners, WHAMM and FILIP1 in the 
regulation of actin cytoskeletal dynamics, cell adhesion and migration  
Paper I: RhoD regulates cytoskeletal dynamics via the actin nucleation–promoting factor 
WASp homologue associated with actin, Golgi membranes and microtubules. 
 
The present notion about RhoD is that it inhibits endosome dynamics and cell motility 
[203]. Ectopic expression of RhoD leads to dramatic effects on the organization of actin 
filament system observed as long flexible filopodia protrusions and formation of short 
bundles of actin filaments [205]. FILIP1 was initially identified in 2002, as a Filamin A 
(FLNa) binding protein and was shown to have a role in the degradation of FLNa, 
suggesing that FILIP1 overexpression results in the decreased cell migration [219]. FLNa 
organizes actin networks by binding with the pre-existing actin filaments to form 
orthogonal lattices of filaments.  
Intriguingly, after identification of FILIP1 as a RhoD-binding protein, a sequence similarity 
to WHAMM was noticed. More specifically, FILIP1 and WHAMM possess distinct 
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homology in their domain organization particularly in the structural maintenance of 
chromosome (SMC) domain. WHAMM does not bind Filamin-A (FLNa) instead it binds 
to the Arp2/3 complex and functions as an NPF. Previous studies suggest that FLNa is 
needed for cell motility via the organization of lamellipodia; knocking down of FLNa leads 
to defective cell migration of neural cells into the ventricular zone [219]. WHAMM 
localizes to the cis-side of Golgi apparatus [220]. It is clear that WHAMM has the ability to 
trigger actin polymerization. However, most of its functions seem to be associated with 
bundling of microtubules and Golgi homeostasis.  
Overexpression of RhoD active variant in endothelial cell negatively effects cell migration 
[139]. Results from our experiments indicate that knocking down of both WHAMM and 
RhoD decreases cell migration in BJ/SV40T fibroblasts observed in wound closure assay. 
Furthermore, we observed a significant increase in focal adhesion size in cells depleted of 
RhoD or WHAMM. Moreover, these cells adhered more firmly to substratum. In 
conclusion, our data suggests a unique role of less studied member of Rho GTPases 
subfamily RhoD in cell migration and cell adhesion via its effectors, FILIP1 and 
WHAMM. 
 
To clarify the role of RhoD, via its effectors, WHAMM and FILIP1 in the 
regulation of protein transport from ER to cell membrane via Golgi. 
Paper II: RhoD regulates ER to Golgi transport through its effectors Filamin A-binding 
protein FILIP1 and WHAMM 
 
The described role of WHAMM in Golgi homeostasis stimulated us to study the 
subcellular localization of RhoD in more detail. Previously, RhoD has been shown to 
localize to early endosome vesicles and cell membrane. We made an observation that 
endogenous RhoD localizes to the Golgi complex based on the colocalization with the 
Golgi markers, GM130 and TGN46. We confirmed this by co-expressing RhoD and 
ArfGAP, a known Golgi apparatus morphology maintenance protein and observed a 
colocalization between RhoD and ArfGAP. Upon overexpression of active and the 
dominant negative variants of RhoD (i.e., G26V and T31N respectively) in Cos1 and 
BJ/SV40T cells, we observed dispersion of the Golgi apparatus. RhoD/T31N had more 
prominent effect on the Golgi disruption. Similar effects were observed upon 
overexpression of WHAMM and FILIP1, indicating the presence of a RhoD-dependent 
signaling pathway in the regulation of Golgi homeostasis. 
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We measured and quantified this disruption of ER-to-Golgi transport using RhoD/T31N, 
together with a temperature sensitive mutant of vesicular stomatitis virus coat protein 
(EGFP-VSV-G). We reasoned that dominant negative variant of RhoD might affect the 
transport of this virus-derived protein from ER-to-Golgi. In this assay, at 40oC, VSV-G 
is misfolded and confined to ER. Upon a downshift in the temperature to 32oC this viral 
protein refolds and funnels through the ER to the plasma membrane via Golgi [218]. A 
drastic difference in the VSV-G protein transport was observed in the cells 
overexpressing RhoD/T31N as compared to control cells. Similar effects on the VSV-G 
transport were observed in WHAMM and FILIP1 overexpressing cells. WHAMM 
showed a predominant effect on the transport by trapping the VSV-G protein in ER even 
after 60 minutes.  FILIP1 had a weaker effect and delayed the VSV-G transport by 
holding half of the protein in ER post 60 minutes. 
While overexpression of RhoD and its effectors i.e., FILIP1 and WHAMM showed a 
dramatic effect on protein transport and Golgi disruption, knocking down by siRNA 
targeting RhoD, FILIP1 and/or WHAMM also affected Golgi homeostasis in BJ/SV40T 
cells. Knocking down of RhoD, WHAMM and FILIP1 resulted in dispersion of Golgi 
membranes. Comparatively, WHAMM induced less Golgi dispersion. In conclusion, the 
work in this paper describes that RhoD, via its effectors, WHAMM and FILIP1 
interferes with the protein transport from ER-to-Golgi. Also, it shows that a shift in the 
balance of RhoD levels and its binding partners interferes with Golgi homeostasis.   
 
To determine the role of RhoD, via the Rab5 effector Rabankyrin-5 in receptor 
tyrosine kinases trafficking 
 Paper III: RhoD binds the Rab5 effector Rabankyrin-5 and has a role in trafficking of 
receptor tyrosine kinases 
 
The data in this manuscript describes the role of RhoD via its novel effector, 
Rabankyrin-5 in the trafficking of receptor tyrosine kinase (PDGFβ). Rabankyrin-5 is a 
known effector for the Rab5 GTPase and is involved in early endosome and 
macropinosome motility in epithelial cells. Ectopic expression of Rabankyrin-5 has been 
well documented to increase macropinosome number and enhance fluid uptake in 
MDCK epithelial and fibroblasts cells [221]. By knocking down of Rabankyrin-5 in 
these cells reduces the macropinosome number. 
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We found that RhoD binds to Rabankyrin-5. Also, Rabankyrin-5 coordinates RhoD and 
Rab5 in the trafficking of early endosomes. A study by Gasman et al. showed that the 
active variant of RhoD/G26V localizes to early endosome vesicles and has a role in 
endosome trafficking [203]. In that study, it was observed that ectopically expressed 
RhoD inhibited Rab5-dependent effects and caused the formation of more spherical, 
scattered and small endosome vesicles. This RhoD-dependent effect on vesicle 
trafficking was observed to be independent of Rab5 overexpression, which suggests that 
RhoD is sufficient to disturb endosomal movement. Our data demonstrates that 
knocking down of RhoD and/or Rabankyrin-5 affects endocytosis. This was checked by 
impeding the internalization of receptor tyrosine kinase, PDGFR-β. In conclusion, our 
study demonstrates that RhoD controls endosome vesicle trafficking and endocytosis, 
presumably via the novel RhoD effector Rabankyrin-5. 
 
To dissect the mechanism by which the interaction of RhoD and ZIPk regulates the 
actin filament assembly and focal adhesion dynamics  
 Paper IV: Interaction of RhoD and ZIP kinase modulates actin filament assembly and   
focal adhesion dynamics  
 
This study gives an account of RhoD via its effector, Zipper Interacting Protein kinase 
(ZIPk) in regulating actin and focal adhesion reorganization. ZIPk is a serine/threonine 
kinase implicated in programmed cell death. This protein is also known as death-
associated protein kinase 3, DAPK3 and belongs to death-associated protein family 
(DAPk). Members of this protein kinase family share great deal of similarity in their 
catalytic (kinase) domain and also cell-death related functions [222]. Close to N-
terminus of the ZIPk protein is the kinase domain and it is due to this domain that 
DAPk, DRP-1 and ZIPk make a subfamily. Outside this region, this subfamily varies in 
size and structure. Upon upregulation of these kinases, cells undergo morphological 
changes that lead to programmed cell death by cell rounding and membrane blebbing. 
ZIPk has been implicated in the control of filamentous actin via myosin regulatory light 
chain phosphorylation (MRLC). We observed that RhoD interacts with ZIPk in a GTP-
dependent manner. Additionally, we also tested the interaction between a point mutant 
and a deletion mutant of ZIPk (i.e., kinase dead mutant D161A and mutant lacking the 
C-terminal leucine zipper domain/ΔLZ) with both the active variant of RhoD/G26V as 
well as the dominant negative RhoD/T31N. We observed that the ZIPk/ΔLZ mutant did 
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not interact with RhoD in a GTP-dependent manner. However, the kinase dead D161A 
mutant did interact with RhoD in a GTP-dependent manner. Additionally, we found that 
overexpression of ZIPk induces the reorganization of the actin filament system observed 
as condensed stress fibres into thick bundles appearing like a star shape, similar to a 
phenotype described before [223]. Moreover, overexpression of the ZIPk also induces 
membrane blebbing that was not linked to reduced cell adhesion. Our data shows that 
both kinase dead mutant (D161A) and the C-terminus deletion mutant (ZIPk/ΔLZ) did 
not affect the organization of stress fibres. We also observed that while the ZIPk wild 
type and its kinase dead counterpart localize to the cell cytoplasm, the ΔLZ mutant 
localizes in the nucleus of fibroblast cells. This can indicate a role of LZ domain in the 
localization of ZIPk. Intriguingly, overexpressing ZIPk together with either RhoD wild 
type or active variant, RhoD/G2V, suppresses the ZIPk-induced stress fibre bundling. 
The constitutively active RhoD mutant, RhoD/G26V, suppressed ZIPk-induced 
membrane blebbing, thereby reverting the phenotype to the normal fibroblast cells 
morphologically. However, the wild-type RhoD, dominant negative RhoD/T31N mutant 
and a membrane targeting-defective mutant of RhoD failed to suppress ZIPk-induced 
blebbing. This suggests that the suppressing and the membrane targeting abilities of 
RhoD are dependent on the GTP-loaded status of RhoD.  
After observing that overexpressed ZIPk had a profound effect on stress fibre 
organisation, we tested the effect of ZIPk on focal adhesion organization. Wild type 
ZIPk overexpression resulted in a dramatic increase in focal adhesion size. It was only 
the wild type ZIPk that could increase the focal adhesion size and not kinase dead 
mutant of the ZIPk (D161A). When ZIPk was coexpressed with active variant of 
RhoD/G26V, the focal adhesion size was suppressed. Focal adhesion dynamics is 
related to the activity of focal adhesion kinase (FAK). FAK is activated by integrins via 
disruption of auto-inhibitory conformation. The phosphorylated tyrosine residue pY397 is 
positively correlated with the FAK activation. Fibroblast cells ectopically expressing 
ZIPk resulted in decreased phospho-Y397 and so did the kinase dead D161A mutant. 
However, the ZIPk/ΔLZ mutant did not have any effect on phospho-Y397. On the other 
hand, overexpression of RhoD alone did not change Y397 phosphorylation significantly 
however, it suppressed the ZIPk-dependent decrease of phospho-Y397. In contrast, the 
phosphorylation on another tyrosine residue, Y576 was not affected significantly upon 
ectopic expression of either ZIPk or RhoD.  
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In essence, our data shows that RhoD interacts with ZIPK in a GTP-dependent manner 
and modulates stress fibers, focal adhesion reorganization and membrane blebbing.  
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5. FUTURE PROSPECTS  
Till date, the best-studied members of Rho subfamily are RhoA, Rac and Cdc42. The 
other members of Rho GTPases have been less studied and their potential roles in 
myriads of cellular processes have not been fully explored. The work in this thesis 
brings forth one of the members of the less studied Rho GTPases subfamily i.e., RhoD.  
Our findings with RhoD have unravelled the role of RhoD in the regulation of cell 
adhesion and migration via novel binding partners i.e., FILIP1 and WHAMM. 
Additionally, with the same effectors, RhoD also has role in regulating ER-to-Golgi 
transport and Golgi homeostasis. Our quest to know more about the function of RhoD 
and effector Rabankryin-5 provids a new understanding and knowledge of how RhoD 
has a role in the internalization and trafficking of the activated receptor tyrosine kinases. 
Subsequent work with binding partner, ZIP kinase, gives an insight into how RhoD via 
its binding partners, ZIP kinase also modulates focal adhesion dynamics and actin 
filament assembly. In summary, this thesis work contributes to our understanding of 
complex regulatory networks mediated by RhoD and the associated biological function. 
With this understanding of RhoD to date, it will be interesting and intriguing to find out 
additional roles of RhoD via its effectors in cell cycle progression or epithelial-
mesenchymal transition, ultimately giving an insight and understanding of the signal 
transduction pathways mediated by RhoD in metastasis and/or cancer progression. 
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AUTHORIZATION LETTER* 
Details of communication with, “The Guardian”, newspaper seeking permission to 
quote a poem in my PhD thesis. 
 
Reply to my email on Wednesday, January 30, 2013 at 11:32:30 AM GMT+01:00 
from: 
Edie Reilly  
Observer Letters 
Letters.Observer@guardian.co.uk 
 
Dear Vishal,  
As far as I'm aware you don't need permission to quote the poem. The only time you 
need permission is if it is going to be reproduced in a publication that will be sold for 
profit. Therefore, you can quote this poem in your PhD thesis. 
Best wishes,  
Edie Reilly  
Observer Letters 
 
On Sunday, January 27, 2013 at 14:33, I emailed Observer letters,“The Guardian”. 
 
Dear Sir/Madam, 
 
I am writing a PhD thesis and I would like to quote an obituary poetry that appeared in 
the ”The Guardian newspaper” in 2003 written by a poet, Mr. Vikram Seth as a 
dedication to my late grandfather. I tried to find out the contact details of Mr. Seth, so 
that I can seek his permission directly but had no luck. I would appreciate, if you could 
help me in getting his permission so that I can quote his poetry in my thesis. 
I look forward to hearing from you. 
With regards, 
Vishal 
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